Sun Pharma Q1 Review - Superior Performance Across Segments Led To Strong Earnings Beat: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Sun Pharmaceutical Industries Ltd.’s Q1 FY22 earnings were well above our expectation, led by over 25% growth in all segments, except active pharmaceutical ingredient.
Steady traction in the specialty portfolio, recovery in the core portfolio of branded generics, new launches in U.S. generics, and partial benefit of Covid-19-related products led to strong growth in Q1 FY22 earnings.
We remain positive on Sun Pharma on the back of:
its strategy of new chemical entity-led brand building in developed markets,
industry leading market share in the branded generics market of domestic formulation, emerging market, and rest of world,
its complex generics pipeline and improving operating leverage.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.